Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?

Anink, J.; Otten, M.H.; Gorter, S.L.; Prince, F.H.M.; Rossum, M.A.J. van; Berg, J.M. van den; ... ; Suijlekom-Smit, L.W.A. van (2013)

Article / Letter to editor

• juvenile idiopathic arthritis
• TNF-alpha inhibitors
• qualitative research
• decision making

• All authors: Anink, J.; Otten, M.H.; Gorter, S.L.; Prince, F.H.M.; Rossum, M.A.J. van; Berg, J.M. van den; Pelt, P.A. van; Kamphuis, S.; Brinkman, D.M.C.; Swen, W.A.A.; Swart, J.F.; Wulffraat, N.M.; Dolman, K.M.; Koopman-Keemink, Y.; Hoppenreijs, E.P.A.H.; Armbrust, W.; Cate, R. ten; Suijlekom-Smit, L.W.A. van
• Date: 2013-09-30
• Journal: Rheumatology
• Volume: 52
• Issue: 9
• Pages: 1674 - 1679
• DOI: doi:10.1093/rheumatology/ket170